Improving Nausea and Vomiting Post-Elipse Balloon: a Novel Single-Dose Regimen of 300 mg Netupitant/0.5 mg Palonosetron Hydrochloride

Ienca, Roberta; Giardiello, Cristiano; Scozzarro, A.; Cola, Rita Schiano di; Lorenzo, Nicola Di; Juneja, Girish; Lopez, Giancarlo Ferretiz; Badiuddin, Faruq

doi:10.1007/s11695-019-03937-x

Cited by 5 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is currently believed that there are multiple factors from three aspects affecting PONV from published studies (8). However, there is still insufficient one study systematically analyzing the effects of all the multiple factors from three aspects of PONV.…”

Section: Introductionmentioning

confidence: 99%

Risk factors of postoperative nausea and vomiting after total hip arthroplasty or total knee arthroplasty: a retrospective study

et al. 2020

View full text Add to dashboard Cite

Background: Postoperative nausea and vomiting (PONV) is a common complication after total hip/knee arthroplasty (THA/TKA) that affects patient satisfaction and postoperative recovery. It has been reported that patients undergoing THA/TKA experience PONV at a frequency of 20-83%. This study investigates the occurrence of PONV in patients and analyzes the risk factors.Methods: Patients undergoing primary THA/TKA under general anesthesia from October 1, 2017, to May 1, 2018, were included. Data on patient-related factors were collected before THA/TKA. Anesthesiaand surgery-related factors were recorded postoperatively. Risk factors were analyzed using binary logistic regression.Results: A stronger association of motion sickness and PONV was found at six hours after bilateral THA/ TKA [nausea: odds ratio (OR) =14. 648, vomiting: OR =8.405,]. At 6-24 hours after bilateral THA/TKA, patients who had a history of migraines tended to experience nausea (OR =12.589, 1.978-80.105). Patients with lower body mass index (BMI) were more likely to experience PONV at 24-72 hours (nausea: OR =0.767, 0.616-0.954; vomiting: OR =0.666, 0.450-0.983) after bilateral THA/TKA. Conclusions:The incidence of PONV after primary bilateral THA/TKA was higher than that after unilateral THA/TKA. The risk factors vary at different time points after surgery, and a history of motion sickness is the most critical factor affecting PONV.

show abstract

Section: Introductionmentioning

confidence: 99%

Risk factors of postoperative nausea and vomiting after total hip arthroplasty or total knee arthroplasty: a retrospective study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This had been provided to 132 patients and these individuals had an early removal rate of 3.79% which was not significantly less than that for the other cohort of patients who received traditional anti-emetic treatment (4.42%) ( p =0736). However, the current cohort does not represent a large enough study group to draw firm conclusions regarding the benefits of Akynzeo™ in IGB insertion and this should be an area for further additional study as currently there are no other large-scale comparative studies between Akynzeo™ and standard anti-emetic therapy for IGB insertion [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…All patients were given anti-emetic medications at the time of insertion. Towards the end of this data period, Akynzeo™ was utilised as a long-acting anti-emetic given at the time of insertion (gradual introduction from March 2021 onwards) [ 12 ]. Patients were asked to adhere to a dietary regimen which consisted of clear fluids for 2–3 days, followed by graduated progression from nutritious fluids and smooth purees to soft solids and normal diet.…”

Section: Methodsmentioning

confidence: 99%

Safety and Efficacy of 12-Month Intra-gastric Balloon—Series of over 1100 Patients

Wiggins,

Sharma,

Sarfaraz

et al. 2023

OBES SURG

View full text Add to dashboard Cite

Background Intra-gastric balloons (IGB) are a mainstay of endoscopic treatment of overweight and obesity. In recent years, an IGB which can remain in situ for 12 months has been developed. The current study aimed to analyse the safety and efficacy of this 12-month IGB. Methods Consecutive patients receiving the Orbera 365TM IGB (Apollo Endosurgery, TX, USA) between September 2017 and August 2021 were included in a prospective database. Patients received regular follow-up consultations followed by endoscopic removal at 12 months. Demographic data along with weight loss data were collected. All adverse events were recorded. Results In total, 1149 patients were included in the study. A majority of the patients were female (87.13%). Median body mass index (BMI) prior to insertion was 36.30 kg/m2 (IQR 32.60–40.00 kg/m2). Median absolute weight loss for all patients was 11.36 kg (IQR 6.70–16.82 kg). There was ongoing sustained weight loss until device removal at week 52. For patients with a weight recording at point of IGB removal, median weight loss was greater (15.88 kg, IQR 10.43–21.72) with percentage total body weight loss of 15.38% (IQR 10.99–21.77) and excess weight loss of 53.99% (IQR 32.44–76.30). Increased patient engagement with post-procedural follow-up was associated with increased weight loss (p<0.001). There were 60 total complications (5.22%). Fifty patients required balloon removal due to intolerance. There were eight cases of balloon rupture. There were only two severe complications (0.17%). Conclusion The current study has confirmed safety of this IGB at 12 months with adverse events comparable to published literature. Weight loss increased up until the point of removal at 12 months. Graphical Abstract

show abstract

“…Ondansetron and dimenhydrinate are the central drugs in this context. More recently, the netupitant/palonosetron hydrochloride, a potent combination antiemetic drug commonly used to prevent nausea from chemotherapy, has also been shown efficacious in preventing nausea, vomiting, and gastric pain during the IGB adaptation period [ 26 ].…”

Section: New Data On Well-established Proceduresmentioning

confidence: 99%

Endoscopic Procedures for Weight Loss

Brunaldi

Neto

2021

Curr Obes Rep

View full text Add to dashboard Cite

Purpose of Review To provide updated evidence on the endoscopic procedures for weight loss and to bring personal insights on the future of endobariatrics. Recent Findings Intragastric balloons promote significant improvement in histologic and radiologic aspects of non-alcoholic steatohepatitis; the endoscopic sleeve gastroplasty is effective up to 5 years and seems particularly beneficial to patients with BMI≤40kg/m 2 ; distal POSE is a promising technique but still lacks adequate clinical data; aspiration therapy triggers remarkable weight loss, but data on weight trends after removal of the device are still lacking; the satiety-inducing device, the sleeveballoon, the gastric mucosal devitalization, and the endoscopic magnetic partial jejunal diversion are promising procedures still under study and refinements. Summary Several therapeutic options are necessary during obesity’s natural history. Therefore, endobariatrics should act in harmony with lifestyle interventions, diet modification, psychological treatment, pharmacotherapy, and bariatric surgery seeking the best outcome in the long term.

show abstract

Improving Nausea and Vomiting Post-Elipse Balloon: a Novel Single-Dose Regimen of 300 mg Netupitant/0.5 mg Palonosetron Hydrochloride

Cited by 5 publications

References 15 publications

Risk factors of postoperative nausea and vomiting after total hip arthroplasty or total knee arthroplasty: a retrospective study

Risk factors of postoperative nausea and vomiting after total hip arthroplasty or total knee arthroplasty: a retrospective study

Safety and Efficacy of 12-Month Intra-gastric Balloon—Series of over 1100 Patients

Endoscopic Procedures for Weight Loss

Contact Info

Product

Resources

About